Exhibit 2.1
EXECUTION COPY
AGREEMENT AND PLAN OF
MERGER
dated as of
August 12, 2008
among
LONGS DRUG STORES
CORPORATION,
CVS CAREMARK
CORPORATION
and
BLUE MERGERSUB
CORP.
TABLE OF CONTENTS
|
|
|
|
|
|
|
PAGE
|
|
ARTICLE 1
|
|
|
|
D EFINITIONS
|
|
|
|
|
|
|
Section 1.01 .
Definitions
|
|
2
|
|
Section 1.02 . Other Definitional and
Interpretative Provisions
|
|
7
|
|
|
|
|
ARTICLE 2
|
|
|
|
T HE O
FFER
|
|
|
|
|
|
|
Section 2.01. The Offer
|
|
8
|
|
Section 2.02. Company
Action
|
|
10
|
|
Section 2.03. Directors
|
|
11
|
|
Section 2.04 . Top-Up
Option
|
|
12
|
|
|
|
|
ARTICLE 3
|
|
|
|
T HE M
ERGER
|
|
|
|
|
|
|
Section 3.01. The Merger
|
|
13
|
|
Section 3.02. Conversion of
Shares
|
|
14
|
|
Section 3.03. Surrender and
Payment
|
|
14
|
|
Section 3.04. No Dissenters’ or
Appraisal Rights
|
|
16
|
|
Section 3.05 . Stock Options,
Performance Shares and Restricted Shares
|
|
16
|
|
Section 3.06.
Adjustments
|
|
17
|
|
Section 3.07. Withholding
Rights
|
|
17
|
|
Section 3.08. Lost
Certificates
|
|
17
|
|
|
|
|
ARTICLE 4
|
|
|
|
T HE S
URVIVING C ORPORATION
|
|
|
|
|
|
|
Section 4.01. Articles of
Incorporation
|
|
17
|
|
Section 4.02. Bylaws
|
|
18
|
|
Section 4.03. Directors and
Officers
|
|
18
|
|
|
|
|
ARTICLE 5
|
|
|
|
R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY
|
|
|
|
|
|
|
Section 5.01. Corporate Existence and
Power
|
|
18
|
|
Section 5.02. Corporate
Authorization
|
|
18
|
|
Section 5.03. Governmental
Authorization
|
|
19
|
|
Section 5.04.
Non-contravention
|
|
19
|
|
Section 5.05.
Capitalization
|
|
20
|
|
Section 5.06.
Subsidiaries
|
|
21
|
|
Section 5.07. SEC Filings and the
Sarbanes-Oxley Act
|
|
22
|
i
|
|
|
|
|
Section 5.08. Financial
Statements
|
|
23
|
|
Section 5.09. Disclosure
Documents
|
|
23
|
|
Section 5.10. Absence of Certain
Changes
|
|
24
|
|
Section 5.11 . No Undisclosed Material
Liabilities
|
|
24
|
|
Section 5.12. Compliance with Laws and
Court Orders
|
|
25
|
|
Section 5.13. Litigation
|
|
25
|
|
Section 5.14 . Regulatory
Compliance
|
|
25
|
|
Section 5.15 . Taxes
|
|
28
|
|
Section 5.16. Employee Benefit
Plans
|
|
29
|
|
Section 5.17. Environmental
Matters
|
|
32
|
|
Section 5.18 .
Properties
|
|
32
|
|
Section 5.19 . Intellectual
Property
|
|
33
|
|
Section 5.20 . Material
Contracts
|
|
34
|
|
Section 5.21. Finders’
Fees
|
|
35
|
|
Section 5.22 . Opinion of Financial
Advisor
|
|
35
|
|
Section 5.23. Antitakeover
Statutes
|
|
35
|
|
Section 5.24 . No Other Representations
or Warranties
|
|
36
|
|
|
|
|
ARTICLE 6
|
|
|
|
R EPRESENTATIONS AND W ARRANTIES OF P
ARENT
|
|
|
|
|
|
|
Section 6.01. Corporate Existence and
Power
|
|
36
|
|
Section 6.02. Corporate
Authorization
|
|
36
|
|
Section 6.03. Governmental
Authorization
|
|
36
|
|
Section 6.04.
Non-contravention
|
|
37
|
|
Section 6.05. Disclosure
Documents
|
|
37
|
|
Section 6.06. Finders’
Fees
|
|
38
|
|
Section 6.07. Financing
|
|
38
|
|
Section 6.08 . Interim Operations of
Merger Subsidiary
|
|
38
|
|
Section 6.09 .
Litigation
|
|
38
|
|
Section 6.10 . Company
Stock
|
|
38
|
|
Section 6.11 . No Other Representations
or Warranties
|
|
39
|
|
|
|
|
ARTICLE 7
|
|
|
|
C OVENANTS OF THE C OMPANY
|
|
|
|
|
|
|
Section 7.01 . Conduct of the
Company
|
|
39
|
|
Section 7.02. Stockholder Meeting;
Proxy Material
|
|
43
|
|
Section 7.03. Access to
Information
|
|
43
|
|
Section 7.04. No Solicitation; Change
of Recommendation
|
|
44
|
|
Section 7.05. Compensation
Arrangements
|
|
47
|
|
|
|
|
ARTICLE 8
|
|
|
|
C OVENANTS OF P
ARENT
|
|
|
|
|
|
|
Section 8.01. Obligations of Merger
Subsidiary
|
|
47
|
|
Section 8.02. Voting of
Shares
|
|
47
|
ii
|
|
|
|
|
Section 8.03.
Director and Officer Liability
|
|
48
|
|
Section 8.04. Employee
Matters
|
|
49
|
|
|
|
|
ARTICLE 9
|
|
|
|
C OVENANTS OF P
ARENT AND THE C OMPANY
|
|
|
|
|
|
|
Section 9.01. Reasonable Best
Efforts
|
|
51
|
|
Section 9.02 . HSR
Clearance
|
|
52
|
|
Section 9.03. Cooperation
|
|
53
|
|
Section 9.04. Public
Announcements
|
|
54
|
|
Section 9.05. Further
Assurances
|
|
54
|
|
Section 9.06. Merger Without Meeting of
Stockholders
|
|
54
|
|
Section 9.07. Notices of Certain
Events
|
|
54
|
|
Section 9.08 . Takeover
Statutes
|
|
55
|
|
|
|
|
ARTICLE 10
|
|
|
|
C ONDITIONS TO THE M ERGER
|
|
|
|
|
|
|
Section 10.01. Conditions to the
Obligations of Each Party
|
|
55
|
|
|
|
|
ARTICLE 11
|
|
|
|
T ERMINATION
|
|
|
|
Section 11.01.
Termination
|
|
56
|
|
Section 11.02. Effect of
Termination
|
|
57
|
|
|
|
|
ARTICLE 12
|
|
|
|
M ISCELLANEOUS
|
|
|
|
|
|
|
Section 12.01. Notices
|
|
57
|
|
Section 12.02. Survival of
Representations and Warranties
|
|
58
|
|
Section 12.03. Amendments and
Waivers
|
|
58
|
|
Section 12.04. Expenses
|
|
59
|
|
Section 12.05 . Disclosure Schedule
References
|
|
60
|
|
Section 12.06. Binding Effect; Benefit;
Assignment
|
|
61
|
|
Section 12.07. Governing
Law
|
|
61
|
|
Section 12.08.
Jurisdiction
|
|
61
|
|
Section 12.09. WAIVER OF JURY
TRIAL
|
|
62
|
|
Section 12.10. Counterparts;
Effectiveness
|
|
62
|
|
Section 12.11. Entire
Agreement
|
|
63
|
|
Section 12.12.
Severability
|
|
63
|
|
Section 12.13. Specific
Performance
|
|
63
|
iii
AGREEMENT AND PLAN OF
MERGER
AGREEMENT AND PLAN OF MERGER (this
“ Agreement ”) dated as of August 12, 2008,
among Longs Drug Stores Corporation, a Maryland corporation (the
“ Company ”), CVS Caremark Corporation, a
Delaware corporation (“ Parent ”), and Blue
MergerSub Corp., a Maryland corporation and a wholly-owned indirect
subsidiary of Parent (“ Merger Subsidiary
”).
WHEREAS, the respective boards of
directors of Parent and Merger Subsidiary have determined that it
is in the best interests of their respective stockholders, and the
board of directors of the Company (the “ Board of
Directors ”) has determined that it is advisable, for
Parent to acquire the Company on the terms and conditions set forth
herein;
WHEREAS, on the terms and conditions
set forth herein, Merger Subsidiary has agreed to commence a tender
offer (as it may be amended from time to time as permitted by this
Agreement, the “ Offer ”) to purchase all
outstanding shares of common stock, par value $0.50 per share, of
the Company (“ Shares ”) at a price of $71.50
per Share, in cash without interest (such price, or any higher
price as may be paid in the Offer in accordance with this
Agreement, the “ Offer Price ”);
WHEREAS, following consummation of
the Offer, Merger Subsidiary will be merged with and into the
Company (the “ Merger ”), with the Company
surviving the Merger as a direct or indirect wholly owned
subsidiary of Parent in accordance with the Maryland General
Corporation Law (“ Maryland Law ”), and each
Share that is not tendered and accepted pursuant to the Offer
(other than Shares owned by Parent or any direct or indirect wholly
owned subsidiary of Parent or the Company) will thereupon be
canceled and converted into the right to receive cash in an amount
equal to the Offer Price, in each case, on the terms and conditions
set forth herein;
WHEREAS, the Board of Directors
(A) has, by unanimous vote, (i) determined that this
Agreement and the transactions contemplated hereby, including the
Offer and the Merger, are advisable and in the best interests of
the Company and its stockholders on the terms and conditions set
forth herein and (ii) adopted this Agreement and approved the
transactions contemplated hereby, including the Offer and the
Merger, on the terms and conditions substantially as set forth
herein, and (B) has unanimously resolved to recommend that the
Company’s stockholders accept the Offer, tender their Shares
into the Offer and, if required by Applicable Law, approve the
Merger; and
WHEREAS, the respective boards of
directors of Parent and Merger Subsidiary have adopted, approved
and declared advisable, and Parent has caused the sole stockholder
of Merger Subsidiary to approve, this Agreement providing for the
Offer and the Merger in accordance with Maryland Law upon the terms
and conditions set forth herein.
NOW, THEREFORE, in consideration of
the representations, warranties, covenants and agreements contained
in this Agreement, and intending to be legally bound hereby,
Parent, Merger Subsidiary and the Company hereby agree as
follows:
ARTICLE 1
D EFINITIONS
Section 1.01
. Definitions. (a) As
used herein, the following terms have the following
meanings:
“ Acquisition Proposal
” means, other than the transactions contemplated by this
Agreement, any Third-Party offer, proposal or inquiry relating to,
or any Third-Party indication of interest in, (i) any
acquisition or purchase, direct or indirect, of 15% or more of the
consolidated assets of the Company and its Subsidiaries or 15% or
more of any class of equity or voting securities of the Company or
any of its Subsidiaries whose assets, individually or in the
aggregate, constitute 15% or more of the consolidated assets of the
Company, (ii) any tender offer (including a self-tender offer)
or exchange offer that, if consummated, would result in any Third
Party beneficially owning 15% or more of any class of equity or
voting securities of the Company or any of its Subsidiaries whose
assets, individually or in the aggregate, constitute 15% or more of
the consolidated assets of the Company, (iii) a merger,
consolidation, share exchange, business combination, sale of
substantially all the assets, reorganization, recapitalization,
liquidation, dissolution or other similar transaction involving the
Company or any of its Subsidiaries whose assets, individually or in
the aggregate, constitute 15% or more of the consolidated assets of
the Company or (iv) any other transaction the consummation of
which could reasonably be expected to impede, interfere with,
prevent or materially delay the Offer or Merger or that could
reasonably be expected to dilute materially the benefits to Parent
of the transactions contemplated hereby.
“ Affiliate ”
means, with respect to any Person, any other Person directly or
indirectly controlling, controlled by or under common control with
such Person.
“ Applicable Law
” means, with respect to any Person, any foreign, federal,
state or local law (statutory, common or otherwise), constitution,
treaty, convention, ordinance, code, rule, regulation, order,
injunction, judgment, decree, ruling or other similar requirement
enacted, adopted, promulgated or applied by a Governmental
Authority that is binding upon or applicable to such Person, as
amended unless expressly specified otherwise.
“ Business Day ”
means a day other than Saturday, Sunday or other day on which
commercial banks in New York, New York are authorized or required
by Applicable Law to close.
2
“ Code ” means
the Internal Revenue Code of 1986, as amended.
“ Company Balance Sheet
” means the consolidated balance sheet of the Company as of
January 31, 2008 and the footnotes thereto set forth in the
Company 10-K.
“ Company Balance Sheet
Date ” means January 31, 2008.
“ Company Disclosure
Schedule ” means the disclosure schedule dated the date
hereof regarding this Agreement that has been provided by the
Company to Parent and Merger Subsidiary.
“ Company Material Adverse
Effect ” means a material adverse effect on (i) the
condition (financial or otherwise), business, assets or results of
operations of the Company and its Subsidiaries, taken as a whole,
excluding any effect arising out of or resulting from
(A) changes in the financial or securities markets or general
economic or political conditions in the United States not having a
materially disproportionate effect on the Company and its
Subsidiaries, taken as a whole, (B) changes (including changes
of Applicable Law or applicable accounting regulations) or
conditions generally affecting the industry or the geographic
markets in which the Company and its Subsidiaries operate and not
specifically relating to or having a materially disproportionate
effect on the Company and its Subsidiaries, taken as a whole,
(C) acts of war, sabotage or terrorism or natural disasters
involving the United States of America not having a materially
disproportionate effect on the Company and its Subsidiaries, taken
as a whole, or (D) the announcement or consummation of the
transactions contemplated by this Agreement, or (ii) the
Company’s ability to consummate the transactions contemplated
by this Agreement.
“ Company 10-K ”
means the Company’s annual report on Form 10-K for the fiscal
year ended January 31, 2008.
“ Environmental Laws
” means any Applicable Laws or any agreement with any
Governmental Authority or other third party, relating to human
health and safety, the environment or to Hazardous
Substances.
“ Environmental Permits
” means all permits, licenses, franchises, certificates,
approvals and other similar authorizations of Governmental
Authorities relating to or required by Environmental Laws and
affecting, or relating to, the business of the Company or any of
its Subsidiaries as currently conducted.
“ ERISA ” means
the Employee Retirement Income Security Act of 1974.
“ ERISA Affiliate
” of any entity means any other entity that, together with
such entity, would be treated as a single employer under
Section 414 of the Code.
3
“ GAAP ” means
generally accepted accounting principles in the United
States.
“ Governmental
Authority ” means any transnational, domestic or foreign
federal, state or local, governmental, regulatory or administrative
authority, department, court, agency or official, including any
political subdivision thereof.
“ Hazardous Substance
” means any pollutant, contaminant, waste or chemical or any
toxic, radioactive, ignitable, corrosive, reactive or otherwise
hazardous substance, waste or material, or any substance, waste or
material having any constituent elements displaying any of the
foregoing characteristics, including any substance, waste or
material regulated under any Environmental Law.
“ HSR Act ” means
the Hart-Scott-Rodino Antitrust Improvements Act of
1976.
“ Intellectual Property
” means (i) trademarks, service marks, brand names,
certification marks, trade dress, domain names and other
indications of origin, the goodwill associated with the foregoing
and registrations in any jurisdiction of, and applications in any
jurisdiction to register, the foregoing, including any extension,
modification or renewal of any such registration or application,
(ii) inventions and discoveries, whether patentable or not, in
any jurisdiction, patents, applications for patents (including
divisions, continuations, continuations in part and renewal
applications), and any renewals, extensions or reissues thereof, in
any jurisdiction, (iii) Trade Secrets, (iv) writings and
other works, whether copyrightable or not, in any jurisdiction, and
any and all copyright rights, whether registered or not, and
registrations or applications for registration of copyrights in any
jurisdiction, and any renewals or extensions thereof,
(v) moral rights, database rights, design rights, industrial
property rights, publicity rights and privacy rights and
(vi) any similar intellectual property or proprietary
rights.
“ IT Assets ”
means computers, computer software, firmware, middleware, servers,
workstations, routers, hubs, switches, data communications lines
and all other information technology equipment, and all associated
documentation owned by the Company or its Subsidiaries or licensed
or leased by the Company or its Subsidiaries pursuant to written
agreement (excluding any public networks and
“off-the-shelf” or “shrink-wrap”
items).
“ knowledge ” of
(i) the Company means the knowledge of any of the individuals
set forth on Section 1.01 of the Company Disclosure Schedule
after reasonable inquiry and (ii) Parent or any of its
Subsidiaries means the knowledge of any of the individuals set
forth on Section 1.01 of the Parent Disclosure Schedule after
reasonable inquiry.
4
“ Lien ” means,
with respect to any property or asset, any mortgage, lien, pledge,
charge, security interest, encumbrance or other adverse claim of
any kind in respect of such property or asset. For purposes of this
Agreement, a Person shall be deemed to own subject to a Lien, any
property or asset that it has acquired or holds subject to the
interest of a vendor or lessor under any conditional sale
agreement, capital lease or other title retention agreement
relating to such property or asset.
“ 1933 Act ”
means the Securities Act of 1933.
“ 1934 Act ”
means the Securities Exchange Act of 1934.
“ Parent Disclosure
Schedule ” means the disclosure schedule dated the date
hereof regarding this Agreement that has been provided by Parent to
the Company.
“ Parent Material Adverse
Effect ” means a material adverse effect on
Parent’s ability to consummate the transactions contemplated
by this Agreement.
“ Permitted Liens
” means any Lien that is (i) not material in amount and
(ii) does not materially detract from the value of, or
materially impair the existing use of, the asset affected by such
Lien.
“ Person ” means
an individual, corporation, partnership, limited liability company,
association, trust or other entity or organization, including a
government or political subdivision or an agency or instrumentality
thereof.
“ Sarbanes-Oxley Act
” means the Sarbanes-Oxley Act of 2002.
“ SEC ” means the
Securities and Exchange Commission.
“ Subsidiary ”
means, with respect to any Person, any entity of which securities
or other ownership interests having ordinary voting power to elect
a majority of the board of directors or other persons performing
similar functions are at any time directly or indirectly owned by
such Person.
“ Third Party ”
means any Person, including as defined in Section 13(d) of the
1934 Act, other than Parent or any of its Affiliates.
“ WARN Act ”
means the Worker Adjustment and Retraining Notification
Act.
5
(b) Each of the following terms is
defined in the Section set forth opposite such term:
|
|
|
|
|
|
|
Section
|
|
Acceptance Time
|
|
2.01
|
|
Adverse Recommendation Change
|
|
7.04
|
|
Agreement
|
|
Preamble
|
|
Board of Directors
|
|
Preamble
|
|
Certificates
|
|
3.03
|
|
Closing
|
|
3.01
|
|
Company Board Recommendation
|
|
5.02
|
|
Company Disclosure Documents
|
|
5.09
|
|
Company Financial Advisor
|
|
5.21
|
|
Company Proxy Statement
|
|
5.09
|
|
Company Restricted Share
|
|
3.05
|
|
Company SEC Documents
|
|
5.07
|
|
Company Securities
|
|
5.05
|
|
Company Stock Option
|
|
3.05
|
|
Company Subsidiary Securities
|
|
5.06
|
|
Company Stockholder Meeting
|
|
7.02
|
|
Compensation Arrangement
|
|
5.16
|
|
Compensation Arrangement Approvals
|
|
5.16
|
|
Compensation Committee
|
|
5.16
|
|
Confidentiality Agreement
|
|
7.03
|
|
Continuing Employees
|
|
8.04
|
|
D&O Insurance
|
|
8.03
|
|
Deemed Assignment Transaction
|
|
9.03
|
|
Effective Time
|
|
3.01
|
|
Employee Plans
|
|
5.16
|
|
End Date
|
|
11.01
|
|
Exchange Agent
|
|
3.03
|
|
Healthcare Information Laws
|
|
11.01
|
|
Healthcare Regulatory Approvals
|
|
5.03
|
|
Indemnified Person
|
|
8.03
|
|
Independent Directors
|
|
2.03
|
|
Lease
|
|
5.18
|
|
Maryland Law
|
|
Preamble
|
|
Material Contracts
|
|
5.20
|
|
Merger
|
|
Preamble
|
|
Merger Consideration
|
|
3.02
|
|
MEWA
|
|
5.16
|
|
Minimum Condition
|
|
2.01
|
|
Multiemployer Plan
|
|
5.16
|
|
Notice of Merger
|
|
2.01
|
|
NYSE
|
|
2.04
|
|
Offer
|
|
Preamble
|
|
Offer Documents
|
|
2.01
|
|
Offer Price
|
|
Preamble
|
|
Payment Event
|
|
12.04
|
|
Performance Share
|
|
3.05
|
|
Permits
|
|
5.01
|
|
Process Agent
|
|
12.08
|
6
|
|
|
|
|
Representatives
|
|
7.03
|
|
Requisite Short-Form Merger Shares
|
|
2.04
|
|
Schedule TO
|
|
2.01
|
|
Schedule 14D-9
|
|
2.02
|
|
Shares
|
|
Preamble
|
|
Subsequent Offering Period
|
|
2.01
|
|
Superior Proposal
|
|
7.04
|
|
Surviving Corporation
|
|
3.01
|
|
Takeover Statute
|
|
2.02
|
|
Tax
|
|
5.15
|
|
Taxing Authority
|
|
5.15
|
|
Tax Return
|
|
5.15
|
|
Tax Sharing Agreements
|
|
5.15
|
|
Top-Up Notice
|
|
2.04
|
|
Top-Up Option
|
|
2.04
|
|
Top-Up Shares
|
|
2.04
|
|
Uncertificated Shares
|
|
3.03
|
Section 1.02
. Other Definitional and
Interpretative Provisions . The words “hereof”,
“herein” and “hereunder” and words of like
import used in this Agreement shall refer to this Agreement as a
whole and not to any particular provision of this Agreement. The
captions herein are included for convenience of reference only and
shall be ignored in the construction or interpretation hereof.
References to Articles, Sections, Exhibits, Annexes and Schedules
are to Articles, Sections, Exhibits, Annexes and Schedules of this
Agreement unless otherwise specified. Any capitalized terms used in
any Exhibit, Annex or Schedule but not otherwise defined therein,
shall have the meaning as defined in this Agreement. Any singular
term in this Agreement shall be deemed to include the plural, and
any plural term the singular. Whenever the words
“include”, “includes” or
“including” are used in this Agreement, they shall be
deemed to be followed by the words “without
limitation”, whether or not they are in fact followed by
those words or words of like import. “Writing”,
“written” and comparable terms refer to printing,
typing and other means of reproducing words (including electronic
media) in a visible form. References to any statute shall be deemed
to refer to such statute as amended from time to time and to any
rules or regulations promulgated thereunder. References to any
agreement or contract are to that agreement or contract as amended,
modified or supplemented from time to time in accordance with the
terms hereof and thereof; provided that, with respect to any
agreement or contract listed on any schedules hereto, all such
amendments, modifications or supplements must also be listed in the
appropriate schedule. References to any Person include the
successors and permitted assigns of that Person. References from or
through any date mean, unless otherwise specified, from and
including or through and including, respectively.
7
ARTICLE 2
T HE
O FFER
Section 2.01
. The Offer .
(a) Provided that nothing shall have occurred and be
continuing that, had the Offer been commenced, would give rise to a
right to terminate the Offer pursuant to any of the conditions set
forth in Annex I, as promptly as practicable after the date hereof
and in any event within ten calendar days after the date hereof,
Merger Subsidiary shall commence (within the meaning of Rule 14d-2
under the 1934 Act) the Offer to purchase any and all of the
outstanding Shares at the Offer Price, net to the seller in cash.
The Offer shall only be subject to the condition that there shall
be validly tendered in accordance with the terms of the Offer,
prior to the expiration date of the Offer and not withdrawn, a
number of Shares that, together with the Shares then owned by
Parent and/or Merger Subsidiary, represents at least two-thirds of
the total number of Shares outstanding on a fully diluted basis
(the “ Minimum Condition ”) and to the other
conditions set forth in Annex I. Merger Subsidiary expressly
reserves the right to waive any of the conditions to the Offer and
to make any change in the terms of or conditions to the Offer;
provided that, without the prior consent of the Company,
(i) the Minimum Condition may not be waived and (ii) no
change may be made that changes the form of consideration to be
paid, decreases the Offer Price or the number of Shares sought in
the Offer, imposes conditions to the Offer in addition to those set
forth in Annex I or modifies the conditions set forth in Annex I or
amends any other term of the Offer in any manner adverse to the
holders of Shares. Notwithstanding the foregoing, (x) without
the consent of the Company, Merger Subsidiary shall have the right
to extend the Offer for any period required by any rule,
regulation, interpretation or position of the SEC or the staff
thereof applicable to the Offer or any period required by
Applicable Law and (y) if any condition to the Offer is not
satisfied or waived on any scheduled expiration date of the Offer,
Merger Subsidiary shall extend the Offer from time to time until
such conditions are satisfied or waived; provided , in each
case, that Merger Subsidiary shall not be required to extend the
Offer beyond the End Date. Following expiration of the Offer,
Merger Subsidiary may, in its sole discretion, provide a subsequent
offering period (“ Subsequent Offering Period ”)
in accordance with Rule 14d-11 of the 1934 Act. Merger Subsidiary
shall not terminate or withdraw the Offer other than in connection
with the termination of this Agreement in accordance with Article
11 hereof. Subject to the foregoing, including the requirements of
Rule 14d-11, and upon the terms and subject to the conditions of
the Offer, Merger Subsidiary shall, and Parent shall cause it to,
accept for payment and pay for, as promptly as practicable after
the expiration of the Offer, all Shares (i) validly tendered
and not withdrawn pursuant to the Offer and (ii) validly
tendered in the Subsequent Offering Period (the time at which
Shares are first accepted for payment under the Offer, the “
Acceptance Time ”).
(b) On the date of commencement of
the Offer, Parent and Merger Subsidiary shall (i) file with
the SEC a Tender Offer Statement on Schedule TO with respect to the
Offer (together with all amendments and supplements
thereto
8
and including exhibits thereto, the “
Schedule TO ”) that shall include the summary term
sheet required thereby and, as exhibits, the Offer to Purchase and
a form of letter of transmittal and summary advertisement and other
appropriate ancillary Offer documents (collectively, together with
any amendments or supplements thereto, the “ Offer
Documents ”) and (ii) cause the Offer Documents,
along with the notice of the Merger required by
Section 3-106(d)(1) of Maryland Law (the “ Notice of
Merger ”), to be disseminated to holders of Shares. Each
of Parent, Merger Subsidiary and the Company agrees promptly to
correct any information provided by it for use in the Schedule TO,
the Offer Documents or the Notice of Merger if and to the extent
that such information shall have become (or shall become known to
be) false or misleading in any material respect. Parent and Merger
Subsidiary shall use their reasonable best efforts to cause the
Schedule TO as so corrected to be filed with the SEC and the Offer
Documents as so corrected to be disseminated to holders of Shares,
in each case, as soon as reasonably practicable and as and to the
extent required by applicable U.S. federal securities laws. The
Company and its counsel shall be given a reasonable opportunity to
review and comment on the Schedule TO and the Offer Documents each
time before any such document is filed with the SEC, and Parent and
Merger Subsidiary shall give reasonable and good faith
consideration to any comments made by the Company and its counsel.
Parent and Merger Subsidiary shall provide the Company and its
counsel with (i) any comments or other communications, whether
written or oral, that Parent, Merger Subsidiary or their counsel
may receive from time to time from the SEC or its staff with
respect to the Schedule TO or Offer Documents promptly after
receipt of those comments or other communications and (ii) a
reasonable opportunity to participate in the response of Parent and
Merger Subsidiary to those comments and to provide comments on that
response (to which reasonable and good faith consideration shall be
given).
Section 2.02
. Company Action .
(a) The Company hereby consents to the Offer and represents
that the Board of Directors, at a meeting duly called and held has
unanimously (i) determined that this Agreement and the
transactions contemplated hereby, including the Offer and the
Merger, are advisable and in the best interests of the Company and
its stockholders, (ii) adopted this Agreement and approved the
transactions contemplated hereby, including the Offer and the
Merger, in accordance with the requirements of Maryland Law,
(iii) resolved, subject to Section 7.04(b), to recommend
acceptance of the Offer and, if required by Applicable Law,
approval of the Merger by its stockholders and (iv) taken all
other actions necessary to exempt the Offer, the Merger, this
Agreement and the transactions contemplated hereby from any
“fair price”, “moratorium”, “control
share acquisition”, “interested stockholder”,
“business combination” or other similar statute or
regulation promulgated by a Governmental Authority (“
Takeover Statute ”). The Company has been advised that
all of its directors and executive officers who own Shares intend
to tender their Shares pursuant to the Offer. The Company shall
promptly furnish Parent with a list of its stockholders, mailing
labels and any available listing or computer file
containing
9
the names and addresses of all record holders of
Shares and lists of securities positions of Shares held in stock
depositories, in each case, true and correct as of the most recent
practicable date, and shall provide to Parent such additional
information (including updated lists of stockholders, mailing
labels and lists of securities positions) and such other assistance
as Parent may reasonably request in connection with the
Offer.
(b) On the day that the Offer is
commenced, the Company shall file with the SEC and disseminate to
holders of Shares, in each case, as and to the extent required by
applicable U.S. federal securities laws, a
Solicitation/Recommendation Statement on Schedule 14D-9 (together
with any amendments or supplements thereto, the “ Schedule
14D-9 ”) that, subject to Section 7.04(b), shall
reflect the recommendations of the Board of Directors referred to
above. Each of the Company, Parent and Merger Subsidiary agrees
promptly to correct any information provided by it for use in the
Schedule 14D-9 if and to the extent that it shall have become
false or misleading in any material respect. The Company shall use
its reasonable best efforts to cause the Schedule 14D-9 as so
corrected to be filed with the SEC and to be disseminated to
holders of Shares, in each case, as soon as reasonably practicable
and as and to the extent required by applicable U.S. federal
securities laws. Parent and its counsel shall be given a reasonable
opportunity to review and comment on the Schedule 14D-9 each
time before it is filed with the SEC, and the Company shall give
reasonable and good faith consideration to any comments made by
Parent, Merger Subsidiary and their counsel. The Company shall
provide Parent, Merger Subsidiary and their counsel with
(i) any comments or other communications, whether written or
oral, that the Company or its counsel may receive from time to time
from the SEC or its staff with respect to the Schedule 14D-9
promptly after receipt of those comments or other communications
and (ii) a reasonable opportunity to participate in the
Company’s response to those comments and to provide comments
on that response (to which reasonable and good faith consideration
shall be given).
Section 2.03
. Directors .
(a) Effective upon the Acceptance Time, Parent shall be
entitled to designate the number of directors, rounded up to the
next whole number, on the Board of Directors that equals the
product of (i) the total number of directors on the Board of
Directors (giving effect to the election of any additional
directors pursuant to this Section) and (ii) the percentage
that the number of Shares beneficially owned by Parent and/or
Merger Subsidiary (including Shares accepted for payment) bears to
the total number of Shares outstanding, and the Company shall cause
Parent’s designees to be elected or appointed to the Board of
Directors, including by increasing the number of directors and
seeking and accepting resignations of incumbent directors. At such
time, the Company shall also cause individuals designated by Parent
to constitute the number of members, rounded up to the next whole
number, on (A) each committee of the Board of Directors and
(B) as requested by Parent, each board of directors of each
Subsidiary of the Company (and each committee thereof)
that
10
represents the same percentage as such
individuals represent on the Board of Directors. Notwithstanding
the foregoing, until the Acceptance Time, the Company shall use its
reasonable best efforts to ensure that all of the members of the
Board of Directors and such committees and boards as of the date
hereof who are not employees of the Company shall remain members of
the Board of Directors and such committees and boards until the
Effective Time.
(b) The Company’s obligations
to appoint Parent’s designees to the Board of Directors shall
be subject to Section 14(f) of the 1934 Act and Rule 14f-1
promulgated thereunder. The Company shall promptly take all
actions, and shall include in the Schedule 14D-9 such information
with respect to the Company and its officers and directors, as
Section 14(f) and Rule 14f-1 require in order to fulfill its
obligations under this Section. Parent shall supply to the Company
in writing and be solely responsible for any information with
respect to itself and its nominees, officers, directors and
affiliates required by Section 14(f) and Rule 14f-1 and
the Company’s obligations under Section 2.03(b) shall be
subject to the receipt of such information.
(c) Following the election or
appointment of Parent’s designees pursuant to
Section 2.03(a) and until the Effective Time, the approval of
a majority of the directors of the Company then in office who were
not designated by Parent (the “ Independent Directors
”) shall be required to authorize (and such authorization
shall constitute the authorization of the Board of Directors and no
other action on the part of the Company, including any action by
any other director of the Company, shall be required to authorize)
any termination of this Agreement by the Company, any amendment of
this Agreement requiring action by the Board of Directors, any
extension of time for performance of any obligation or action
hereunder by Parent or Merger Subsidiary and any waiver of
compliance with any of the agreements or conditions contained
herein for the benefit of the Company.
Section 2.04
. Top-Up Option .
(a) Subject to Section 2.04(b) and Section 2.04(c), the
Company grants to Merger Subsidiary an irrevocable option, for so
long as this Agreement has not been terminated pursuant to the
provisions hereof (the “ Top-Up Option ”), to
purchase from the Company up to the number of authorized and
unissued Shares equal to the number of Shares that, when added to
the number of Shares owned by Merger Subsidiary at the time of
exercise of the Top-Up Option, constitutes one Share more than the
number of Shares (the “ Requisite Short-Form Merger
Shares ”) entitled to cast 90% of all the votes entitled
to be cast by each group or class of shares entitled to vote as a
group or class on the Merger after the issuance of all Shares to be
issued upon exercise of the Top-Up Option, calculated on a
fully-diluted basis or, as may be elected by Parent, on a primary
basis at the Effective Time (such Shares to be issued upon exercise
of the Top-Up Option, the “ Top-Up Shares
”).
11
(b) The Top-Up Option may be
exercised by Merger Subsidiary, in whole or in part, only once, at
any time during the ten Business Day period following the
Acceptance Time, or if any Subsequent Offering Period is provided,
during the ten Business Day period following the expiration date of
the Subsequent Offering Period, and only if Merger Subsidiary shall
own as of such time less than the Requisite Short-Form Merger
Shares; provided that notwithstanding anything in this
Agreement to the contrary, the Top-Up Option shall not be
exercisable to the extent (i) the issuance of the Top-Up
Shares would require approval of the Company’s stockholders
under Rule 312 of The New York Stock Exchange (the “
NYSE ”) (unless a waiver or exemption therefrom is
obtained from the NYSE), (ii) the number of Shares issuable
upon exercise of the Top-Up Option would exceed the number of
authorized but unissued Shares or (iii) any other provision of
Applicable Law or judgment, injunction, order or decree shall
prohibit the exercise of the Top-Up Option or the delivery of the
Top-Up Shares. The aggregate purchase price payable for the Top-Up
Shares being purchased by Merger Subsidiary pursuant to the Top-Up
Option shall be determined by multiplying the number of such Shares
by the Offer Price, without interest. Such purchase price may be
paid by Merger Subsidiary, at its election, either entirely in cash
or by executing and delivering to the Company a promissory note
having a principal amount equal to such purchase price. Any such
promissory note shall bear interest at the rate of 3% per
annum, shall mature on the first anniversary of the date of
execution and delivery of such promissory note and may be prepaid
without premium or penalty.
(c) In the event Merger Subsidiary
wishes to exercise the Top-Up Option, Merger Subsidiary shall
deliver to the Company a notice (the “ Top-Up Notice
”) setting forth (i) the number of Top-Up Shares that
Merger Subsidiary intends to purchase pursuant to the Top-Up
Option, (ii) the manner in which Merger Subsidiary intends to
pay the applicable purchase price and (iii) the place and time
at which the closing of the purchase of such Top-Up Shares by
Merger Subsidiary is to take place. The Top-Up Notice shall also
include an undertaking signed by Parent and Merger Subsidiary that,
as promptly as practicable following such exercise of the Top-Up
Option, Merger Subsidiary intends to (and Merger Subsidiary shall,
and Parent shall cause Merger Subsidiary to, as promptly as
practicable after such exercise) consummate the Merger in
accordance with Section 3-106 of Maryland Law and as
contemplated by Section 9.06. At the closing of the purchase of the
Top-Up Shares, Parent and Merger Subsidiary shall cause to be
delivered to the Company the consideration required to be delivered
in exchange for the Top-Up Shares, and the Company shall cause to
be issued to Merger Subsidiary a certificate representing the
Top-Up Shares. The parties hereto agree to use their reasonable
best efforts to cause the closing of the purchase of the Top-Up
Shares to occur on the same day that the Top-Up Notice is deemed
received by the Company pursuant to Section 12.01, and if not so
consummated on such day, as promptly thereafter as possible. The
parties further agree to use their reasonable best efforts to cause
the Merger to be consummated in accordance with Section 3-106
of Maryland Law and as contemplated by Section 9.06 as close
in time as possible to (including, to the extent possible, on the
same day as) the issuance of the Top-Up Shares.
12
(d) Parent and Merger Subsidiary
understand that the Top-Up Shares will not be registered under the
1933 Act and will be issued in reliance upon an exemption
thereunder for transactions not involving a public offering. Each
of Parent and Merger Subsidiary represents, warrants and agrees
that the Top-Up Option is being, and the Top-Up Shares will be,
acquired by Merger Subsidiary for the purpose of investment and not
with a view to or for resale in connection with any distribution
thereof within the meaning of the 1933 Act. Any certificates
evidencing Top-Up Shares shall include any legends required by
applicable securities laws.
(e) Parent and the Company shall use
their respective reasonable best efforts to take, or cause to be
taken, all actions and to do, or cause to be done, and assist and
cooperate with each other in doing, all things necessary or
desirable to procure from the NYSE or any other Governmental
Authority any necessary waiver or other exemption from the
requirements of NYSE Rule 312 or other Applicable Law in order to
enable the issuance of the Top-Up Shares to occur without the need
to obtain the approval of holders of a majority of the Shares
present and voting at the Company Stockholder Meeting.
ARTICLE 3
T HE
M ERGER
Section 3.01
. The Merger . (a) At
the Effective Time, Merger Subsidiary shall be merged with and into
the Company in accordance with Maryland Law, whereupon the separate
existence of Merger Subsidiary shall cease, and the Company shall
be the surviving corporation (the “ Surviving
Corporation ”).
(b) Subject to the provisions of
Article 10, the closing of the Merger (the “ Closing
”) shall take place in New York City at the offices of Davis
Polk & Wardwell, 450 Lexington Avenue, New York, New York,
10017 as soon as possible, but in any event no earlier than 30 days
after the date of the Notice of Merger and no later than two
Business Days after the date the conditions set forth in Article 10
(other than conditions that by their nature are to be satisfied at
the Closing, but subject to the satisfaction or, to the extent
permissible, waiver of those conditions at the Closing) have been
satisfied or, to the extent permissible, waived by the party or
parties entitled to the benefit of such conditions, or at such
other place, at such other time or on such other date as Parent and
the Company may mutually agree.
(c) At the Closing, the Company and
Merger Subsidiary shall file articles of merger with the State
Department of Assessments and Taxation of Maryland and make all
other filings or recordings required by Maryland Law in
13
connection with the Merger. The Merger shall
become effective at such time (the “ Effective Time
”) as the articles of merger are duly accepted by the State
Department of Assessments and Taxation of Maryland or at such later
time as may be specified in the articles of merger.
(d) From and after the Effective
Time, the Surviving Corporation shall possess all the rights,
powers, privileges and franchises and be subject to all of the
obligations, liabilities, restrictions and disabilities of the
Company and Merger Subsidiary, all as provided under Maryland
Law.
Section 3.02
. Conversion of Shares . At
the Effective Time, by virtue of the Merger and without any action
on the part of Parent, Merger Subsidiary or the Company:
(a) except as otherwise provided in
Section 3.02(b) or Section 3.02(c), each Share
outstanding immediately prior to the Effective Time shall be
converted automatically into the right to receive the Offer Price,
in cash without interest (the “ Merger Consideration
”);
(b) each Share held by any
Subsidiary of the Company immediately prior to the Effective Time
shall be converted into such number of shares of stock of the
Surviving Corporation such that each such Subsidiary owns the same
percentage of the outstanding capital stock of the Surviving
Corporation immediately following the Effective Time as such
Subsidiary owned in the Company immediately prior to the Effective
Time;
(c) each Share owned by Parent or
any of its Subsidiaries immediately prior to the Effective Time
shall be canceled, and no payment shall be made with respect
thereto; and
(d) each share of common stock of
Merger Subsidiary outstanding immediately prior to the Effective
Time shall be converted into and become one share of common stock
of the Surviving Corporation with the same rights, powers and
privileges as the shares so converted and shall constitute the only
outstanding shares of capital stock of the Surviving Corporation
(except for any such shares resulting from the conversion of Shares
pursuant to Section 3.02(b)).
Section 3.03
. Surrender and Payment .
(a) Prior to the Acceptance Time, Parent shall appoint an
agent that has been approved in advance by the Company (such
approval not to be unreasonably withheld, delayed or conditioned)
(the “ Exchange Agent ”) for the purpose of
exchanging for the Merger Consideration (i) certificates
representing Shares (the “ Certificates ”) or
(ii) uncertificated Shares (the “ Uncertificated
Shares ”). Parent or one of its Subsidiaries shall make
available to the Exchange Agent, as needed, the Merger
Consideration to be paid in respect of the Certificates and the
Uncertificated Shares. Promptly after the Effective Time, Parent
shall send, or shall cause the Exchange Agent to send, to each
holder of Shares at the Effective Time a letter of transmittal
and
14
instructions (which shall specify that the
delivery shall be effected, and risk of loss and title shall pass,
only upon proper delivery of the Certificates or transfer of the
Uncertificated Shares to the Exchange Agent) for use in such
exchange.
(b) Each holder of Shares that have
been converted into the right to receive the Merger Consideration
shall be entitled to receive, upon (i) surrender to the
Exchange Agent of a Certificate, together with a properly completed
letter of transmittal, or (ii) receipt of an
“agent’s message” by the Exchange Agent (or such
other evidence, if any, of transfer as the Exchange Agent may
reasonably request) in the case of a book-entry transfer of
Uncertificated Shares, the Merger Consideration payable for each
Share represented by a Certificate or for each Uncertificated
Share. Until so surrendered or transferred, as the case may be,
each such Certificate or Uncertificated Share shall represent after
the Effective Time for all purposes only the right to receive the
Merger Consideration.
(c) If any portion of the Merger
Consideration is to be paid to a Person other than the Person in
whose name the surrendered Certificate or the transferred
Uncertificated Share is registered, it shall be a condition to such
payment that (i) either such Certificate shall be properly
endorsed or shall otherwise be in proper form for transfer or such
Uncertificated Share shall be properly transferred and
(ii) the Person requesting such payment shall pay to the
Exchange Agent any transfer or other Taxes required as a result of
such payment to a Person other than the registered holder of such
Certificate or Uncertificated Share or establish to the
satisfaction of the Exchange Agent that such Tax has been paid or
is not payable.
(d) After the Effective Time, there
shall be no further registration of transfers of Shares. If, after
the Effective Time, Certificates or Uncertificated Shares are
presented to the Surviving Corporation, they shall be canceled and
exchanged for the Merger Consideration provided for, and in
accordance with the procedures set forth, in this Article
3.
(e) Any portion of the Merger
Consideration made available to the Exchange Agent pursuant to
Section 3.03(a) (and any interest or other income earned
thereon) that remains unclaimed by the holders of Shares six months
after the Effective Time shall be returned to the Surviving
Corporation upon demand, and any such holder who has not exchanged
such Shares for the Merger Consideration in accordance with this
Section 3.03 prior to that time shall thereafter look only to
the Surviving Corporation for payment of the Merger Consideration
in respect of such Shares without any interest thereon.
Notwithstanding the foregoing, none of Parent, the Company, the
Exchange Agent, the Surviving Company or any of their respective
Affiliates shall be liable to any holder of Shares for any amount
paid to a public official pursuant to applicable abandoned
property, escheat or similar laws. Any amounts remaining unclaimed
by holders of Shares two years after the Effective Time (or such
earlier date immediately prior to such time when the amounts would
otherwise escheat to or become property of any Governmental
Authority) shall become, to the extent permitted by Applicable Law,
the property of the Surviving Corporation free and clear of any
claims or interest of any Person previously entitled
thereto.
15
(f) Any portion of the Merger
Consideration made available to the Exchange Agent pursuant to
Section 3.03(a) to pay for Shares for which appraisal rights
have been perfected shall be returned to the Surviving Corporation,
upon demand.
Section 3.04
. No Dissenters’ or
Appraisal Rights. No dissenters’ or appraisal rights
shall be available with respect to the Merger or the other
transactions contemplated hereby.
Section 3.05
. Stock Options, Performance
Shares and Restricted Shares . (a) At the Acceptance Time,
each then-outstanding option to purchase Shares granted under any
employee stock option or compensation plan or arrangement of the
Company (a “ Company Stock Option ”), whether or
not vested or exercisable, shall be converted into the right to
receive, and the Company shall pay to each former holder of any
such converted Company Stock Option at or promptly after the
Acceptance Time an amount in cash equal to the product of
(i) the excess, if any, of the Merger Consideration over the
applicable exercise price per Share of such Company Stock Option
and (ii) the number of Shares such holder could have purchased
(assuming full vesting of such Company Stock Option) had such
holder exercised such Company Stock Option in full immediately
prior to the Acceptance Time.
(b) At the Acceptance Time, each
then-outstanding right to earn a restricted Share under the
Company’s performance-based restricted stock grant program (a
“ Performance Share ”) shall be deemed earned
(i) at maximum, if such Performance Share relates to the
2008/2009 performance cycle, and (ii) target, if such
Performance Share relates to the 2009/2010 performance cycle;
provided , however , that the portion of such
2009/2010 performance award that is not dependent solely on the
Company’s performance in 2009 shall be prorated by a
fraction, the numerator of which is the number of days, elapsed
between February 1, 2008 and the Acceptance Time and the
denominator of which is the number of days in the full 2009/2010
performance cycle. Earned Performance Shares shall be fully vested
and converted into the right to receive the Merger Consideration at
the Acceptance Time, and any Performance Shares not earned in
accordance with the foregoing shall be cancelled without
consideration.
(c) At the Acceptance Time, each
then-outstanding restricted Share granted under any equity or
compensation plan or arrangement of the Company (a “
Company Restricted Share ”) shall vest (and all
restrictions thereon shall immediately lapse) and shall be
converted into the right to receive the Merger Consideration in
accordance with Section 3.02(a).
(d) The Company shall pay the
holders of Company Stock Options and Performance Shares the cash
payments described in this Section 3.05 as soon as
16
reasonably practicable after the Acceptance
Time, but in any event no later than the earlier of (i) the
Company’s next payroll cycle occurring after the five-day
period following the Acceptance Time or (ii) ten Business Days
following the Acceptance Time.
Section 3.06
. Adjustments . If, during
the period between the date of this Agreement and the Effective
Time, the outstanding Shares shall be changed into a different
number of shares or a different class, including by reason of any
reclassification, recapitalization, stock split or combination,
exchange or readjustment of Shares, or stock dividend thereon with
a record date during such period, but excluding any change that
results from any exercise of Company Stock Options, the Offer
Price, the Merger Consideration and any other amounts payable
pursuant to this Agreement shall be appropriately
adjusted.
Section 3.07
. Withholding Rights .
Notwithstanding anything to the contrary contained herein, each of
the Surviving Corporation and Parent shall be entitled to deduct
and withhold from the consideration otherwise payable to any Person
pursuant to Articles 2 and 3 such amounts as it is required to
deduct and withhold with respect to the making of such payment
under any provision of Tax law, and if any such amounts are
deducted and withheld, the Surviving Corporation or Parent, as the
case may be, shall timely pay such amounts over to the appropriate
Government Authority. If the Surviving Corporation or Parent, as
the case may be, so withholds amounts, such amounts shall be
treated for all purposes of this Agreement as having been paid to
the Person in respect of which the Surviving Corporation or Parent,
as the case may be, made such deduction and withholding.
Section 3.08
. Lost Certificates . If any
Certificate shall have been lost, stolen or destroyed, upon the
making of an affidavit of that fact by the Person claiming such
Certificate to be lost, stolen or destroyed, the completion of the
letter of transmittal by such Person and, if required by the
Surviving Corporation, the posting by such Person of a bond, in
such reasonable amount as the Surviving Corporation may direct, as
indemnity against any claim that may be made against it with
respect to such Certificate, the Exchange Agent shall pay, in
exchange for such lost, stolen or destroyed Certificate, the Merger
Consideration to be paid in respect of the Shares represented by
such Certificate, as contemplated by this Article 3.
ARTICLE 4
T HE
S URVIVING C ORPORATION
Section 4.01
. Articles of Incorporation .
The articles of incorporation of the Company in effect at the
Effective Time shall be the articles of incorporation of the
Surviving Corporation until amended in accordance with Applicable
Law.
17
Section 4.02
. Bylaws . The bylaws of
Merger Subsidiary in effect at the Effective Time shall be the
bylaws of the Surviving Corporation until amended in accordance
with Applicable Law.
Section 4.03
. Directors and Officers .
From and after the Effective Time, until successors are duly
elected or appointed and qualified in accordance with Applicable
Law, (i) the directors of Merger Subsidiary at the Effective
Time shall be the directors of the Surviving Corporation and
(ii) the officers of Merger Subsidiary at the Effective Time
shall be the officers of the Surviving Corporation.
ARTICLE 5
R EPRESENTATIONS AND W ARRANTIES OF THE C OMPANY
Subject to Section 12.05,
except as set forth in the Company Disclosure Schedule, the Company
represents and warrants to Parent that:
Section 5.01
. Corporate Existence and
Power . The Company is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of
Maryland, has all corporate powers and has, and has had at all
relevant times, all governmental licenses, authorizations, permits,
consents and approvals (“ Permits ”) required to
carry on its business as now conducted, except for those Permits
the absence of which would not have, individually or in the
aggregate, a Company Material Adverse Effect. The Company is duly
qualified to do business as a foreign corporation and is in good
standing in each jurisdiction where such qualification is
necessary, except for those jurisdictions where failure to be so
qualified would not reasonably be expected to have, individually or
in the aggregate, a Company Material Adverse Effect. The Company
has heretofore made available to Parent true and complete copies of
the articles of incorporation and bylaws of the Company as
currently in effect.
Section 5.02
. Corporate Authorization .
(a) The execution, delivery and performance by the Company of
this Agreement and the consummation by the Company of the
transactions contemplated hereby are within the Company’s
corporate powers and, except for the affirmative vote of the
holders of two-thirds of the outstanding Shares in connection with
the consummation of the Merger (if required by Applicable Law),
have been duly authorized by all necessary corporate action on the
part of the Company. The affirmative vote of the holders of
two-thirds of the outstanding Shares entitled to vote thereon (if
required by Applicable Law) is the only vote of the holders of any
of the Company’s capital stock necessary in connection with
the consummation of the Merger. Assuming due authorization,
execution and delivery hereof by Parent and Merger Subsidiary, this
Agreement constitutes a valid and binding agreement of the Company
enforceable against the Company in accordance with its terms
(subject, in the case of enforceability, to applicable bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and
other laws affecting creditors’ rights generally and general
principles of equity).
18
(b) At a meeting duly called and
held, the Board of Directors has (i) unanimously determined
that this Agreement and the transactions contemplated hereby,
including the Offer and the Merger, are advisable and in the best
interests of the Company and its stockholders,
(ii) unanimously adopted this Agreement and approved the
transactions contemplated hereby, including the Offer and the
Merger, and (iii) unanimously resolved (subject to
Section 7.04) to recommend acceptance of the Offer and
approval of the Merger by its stockholders (such recommendation,
the “ Company Board Recommendation
”).
Section 5.03
. Governmental Authorization
. The execution, delivery and performance by the Company of this
Agreement and the consummation by the Company of the transactions
contemplated hereby require no action by or in respect of, or
filing with, any Governmental Authority, other than (i) the
filing and acceptance for the record of articles of merger with
respect to the Merger with the State Department of Assessments and
Taxation of Maryland and appropriate documents with the relevant
authorities of other states in which the Company is qualified to do
business, (ii) compliance with any applicable requirements of
the HSR Act, (iii) compliance with any applicable requirements
of the 1933 Act, the 1934 Act and any other applicable state or
federal securities laws, (iv) actions required by applicable
Food and Drug Administration, Drug Enforcement Administration,
Medicare/Medicaid, state boards of pharmacy and governmental
controlled substances, federal and state insurance and other
federal and state Governmental Authorities with jurisdiction over
the dispensing or distribution of pharmaceutical products or over
the provision of health care items or services, pharmacy benefit
management services, durable medical equipment, insurance and risk
sharing arrangements and products and services, third-party
administrator, utilization review and liquor authorities approvals,
in each case, to the extent applicable (the “ Healthcare
Regulatory Approvals ”), (v) applicable requirements
of the rules and regulations of the NYSE, (vi) actions
required by the Nevada Gaming Commission and the Nevada State
Gaming Control Board and (vii) any actions or filings the
absence of which would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse
Effect.
Section 5.04
. Non-contravention . The
execution, delivery and performance by the Company of this
Agreement and the consummation of the transactions contemplated
hereby do not and will not (i) contravene, conflict with, or
result in any violation or breach of any provision of the articles
of incorporation or bylaws of the Company, (ii) assuming
compliance with the matters referred to in Section 5.03,
contravene, conflict with, or result in a violation or breach of
any provision of any Applicable Law, (iii) assuming compliance
with the matters referred to in Section 5.03, require any
consent or other action by any Person under, constitute a default,
or an event that, with or
19
without notice or lapse of time or both, would
constitute a default, under, or cause or permit the termination,
cancellation, acceleration or other change of any right or
obligation or the loss of any benefit to which the Company or any
of its Subsidiaries is entitled under any provision of any
agreement or other instrument binding upon the Company or any of
its Subsidiaries or any license, franchise, permit, certificate,
approval or other similar authorization affecting, or relating in
any way to, the assets or business of the Company and its
Subsidiaries or (iv) result in the creation or imposition of
any Lien on any asset of the Company or any of its Subsidiaries,
with only such exceptions, in the case of each of clauses
(ii) through (iv), as would not reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse
Effect.
Section 5.05
. Capitalization .
(a) The authorized capital stock of the Company consists of
(i) 120,000,000 Shares and (ii) 30,000,000 shares of
preferred stock, $0.50 par value per share, of which 300,000 shares
of preferred stock are classified as Series A Junior Participating
Preferred Stock. As of August 6, 2008, there were outstanding
35,930,604 Shares (of which an aggregate of 464,993 are Company
Restricted Shares), no shares of preferred stock, Performance
Shares settleable in 412,000 Shares, and employee stock options to
purchase an aggregate of 1,622,833 Shares (of which options to
purchase an aggregate of 1,313,533 Shares were exercisable). All
outstanding shares of capital stock of the Company have been, and
all shares that may be issued pursuant to any employee stock option
or other compensation plan or arrangement will be, when issued in
accordance with the respective terms thereof, duly authorized and
validly issued, fully paid and nonassessable and free of preemptive
rights. No Subsidiary or Affiliate of the Company owns any shares
of capital stock of the Company.
(b) Section 5.05(b) of the
Company Disclosure Schedule contains a complete and correct list of
(A) each outstanding Employee Stock Option, including the
holder, date of grant, exercise price, vesting schedule and number
of Shares subject thereto, (B) each outstanding Company
Restricted Share, including the holder, date of grant and number
vested and (C) each outstanding Performance Share, including
the holder, date of grant and number of Shares subject
thereto.
(c) There are outstanding no bonds,
debentures, notes or other indebtedness of the Company having the
right to vote (or convertible into, or exchangeable for, securities
having the right to vote) on any matters on which stockholders of
the Company may vote. Except as set forth in this Section 5.05
and for changes since August 6, 2008 resulting from the
exercise of employee stock options outstanding on such date, there
are no issued, reserved for issuance or outstanding (i) shares
of capital stock of or voting securities of the Company,
(ii) securities of the Company convertible into or
exchangeable for shares of capital stock or voting securities of
the Company, (iii) warrants, calls, options or other rights to
acquire from the Company, or other obligation of the Company
to
20
issue, any capital stock or voting securities of
the Company or (iv) restricted shares, stock appreciation
rights, performance units, contingent value rights,
“phantom” stock or similar securities or rights that
are derivative of, or provide economic benefits based, directly or
indirectly, on the value or price of, any capital stock or voting
securities of the Company (the items in clauses (i) though
(iv) being referred to collectively as the “ Company
Securities ”). There are no outstanding obligations of
the Company or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any of the Company Securities. Neither the
Company nor any of its Subsidiaries is a party to any voting
agreement with respect to the voting of any Company
Securities.
Section 5.06
. Subsidiaries .
(a) Each Subsidiary of the Company has been duly organized, is
validly existing and (where applicable) in good standing under the
laws of its jurisdiction of organization, has all organizational
powers and has, and has had at all relevant times, all Permits
required to carry on its business as now conducted, except for
those Permits the absence of which would not have, individually or
in the aggregate, a Company Material Adverse Effect. Each such
Subsidiary is duly qualified to do business as a foreign entity and
is in good standing in each jurisdiction where such qualification
is necessary, except for those jurisdictions where failure to be so
qualified would not have, individually or in the aggregate, a
Company Material Adverse Effect. All material Subsidiaries of the
Company and their respective jurisdictions of organization are
identified in the Company 10-K.
(b) All of the outstanding capital
stock of, or other voting securities or ownership interests in,
each Subsidiary of the Company is owned by the Company, directly or
indirectly, free and clear of any Lien and free of any other
limitation or restriction (including any restriction on the right
to vote, sell or otherwise dispose of such capital stock or other
voting securities or ownership interests). There are no issued,
reserved for issuance or outstanding (i) securities of the
Company or any of its Subsidiaries convertible into or exchangeable
for shares of capital stock of or other voting securities of or
ownership interests in any Subsidiary of the Company,
(ii) warrants, calls, options or other rights to acquire from
the Company or any of its Subsidiaries, or other obligations of the
Company or any of its Subsidiaries to issue, any capital stock of
or other voting securities or ownership interests in, or any
securities convertible into or exchangeable for any capital stock
or other voting securities of or ownership interests in, any
Subsidiary of the Company or (iii) restricted shares, stock
appreciation rights, performance units, contingent value rights,
“phantom” stock or similar securities or rights that
are derivative of, or provide economic benefits based, directly or
indirectly, on the value or price of, any capital stock of, or
other voting securities of or ownership interests in, any
Subsidiary of the Company (the items in clauses (i) through
(iii) being referred to collectively as the “ Company
Subsidiary Securities ”). There are no outstanding
obligations of the Company or any of its Subsidiaries to
repurchase, redeem or otherwise acquire any of the Company
Subsidiary Securities. Except for the capital stock or other equity
or voting interests of its Subsidiaries, the Company does not own,
directly or indirectly, any capital stock or other equity or voting
interests in any Person.
21
Section 5.07
. SEC Filings and the
Sarbanes-Oxley Act . (a) The Company has filed with or
furnished to the SEC, and made available to Parent, all reports,
schedules, forms, statements, prospectuses, registration statements
and other documents required to be filed or furnished by the
Company since January 1, 2005 (collectively, together with any
exhibits and schedules thereto and other information incorporated
therein, the “ Company SEC Documents
”).
(b) As of its filing date (and as of
the date of any amendment), each Company SEC Document complied, and
each Company SEC Document filed subsequent to the date hereof will
comply, as to form in all material respects with the applicable
requirements of the 1933 Act and the 1934 Act, as the case may
be.
(c) As of its filing date (or, if
amended or superseded by a filing prior to the date hereof, on the
date of such filing), each Company SEC Document filed pursuant to
the 1934 Act did not, and each Company SEC Document filed
subsequent to the date hereof will not, contain any untrue
statement of a material fact or omit to state any material fact
necessary in order to make the statements made therein, in the
light of the circumstances under which they were made, not
misleading.
(d) Each Company SEC Document that
is a registration statement, as amended or supplemented, if
applicable, filed pursuant to the 1933 Act, as of the date such
registration statement or amendment became effective, did not
contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to
make the statements therein not misleading.
(e) The Company has established and
maintains disclosure controls and procedures (as defined in Rule
13a-15 under the 1934 Act). Such disclosure controls and procedures
are designed to ensure that material information relating to the
Company, including its consolidated Subsidiaries, is made known to
the Company’s principal executive officer and its principal
financial officer by others within those entities, particularly
during the periods in which the periodic reports required under the
1934 Act are being prepared. Such disclosure controls and
procedures are effective in timely alerting the Company’s
principal executive officer and principal financial officer to
material information required to be included in the Company’s
periodic and current reports required under the 1934 Act. For
purposes of this Agreement, “principal executive
officer” and “principal financial officer” shall
have the meanings given to such terms in the Sarbanes-Oxley
Act.
(f) The Company has established and
maintained a system of internal controls over financial reporting
(as defined in Rule 13a-15 under the 1934 Act) sufficient to
provide reasonable assurance regarding the reliability of the
Company’s financial reporting and the preparation of Company
financial
22
statements for external purposes in accordance
with GAAP. The Company has disclosed, based on its most recent
evaluation of internal controls prior to the date hereof, to the
Company’s auditors and audit committee (i) any
significant deficiencies and material weaknesses in the design or
operation of internal controls which are reasonably likely to
adversely affect the Company’s ability to record, process,
summarize and report financial information and (ii) any fraud,
whether or not material, that involves management or other
employees who have a significant role in internal controls. The
Company has made available to Parent a summary of any such
disclosure made by management to the Company’s auditors and
audit committee since January 1, 2005.
(g) There are no outstanding loans
or other extensions of credit made by the Company or any of its
Subsidiaries to any executive officer (as defined in Rule 3b-7
under the 1934 Act) or director of the Company. The Company has
not, since the enactment of the Sarbanes-Oxley Act, taken any
action prohibited by Section 402 of the Sarbanes-Oxley
Act.
(h) The Company has complied in all
material respects with the applicable listing and corporate
governance rules and regulations of the New York Stock
Exchange.
(i) Each of the principal executive
officer and principal financial officer of the Company (or each
former principal executive officer and principal financial officer
of the Company, as applicable) have made all certifications
required by Rule 13a-14 and 15d-14 under the 1934 Act and Sections
302 and 906 of the Sarbanes-Oxley Act and any related rules and
regulations promulgated by the SEC and the NYSE, and the statements
contained in any such certifications are complete and
correct.
Section 5.08
. Financial Statements . The
audited consolidated financial statements and unaudited
consolidated interim financial statements of the Company included
or incorporated by reference in the Company SEC Documents fairly
present, in conformity with GAAP applied on a consistent basis
(except as may be indicated in the notes thereto), the consolidated
financial position of the Company and its consolidated Subsidiaries
as of the dates thereof and their consolidated results of
operations and cash flows for the periods then ended (subject to
normal year-end audit adjustments in the case of any unaudited
interim financial statements).
Section 5.09
. Disclosure Documents .
(a) Each document required to be filed by the Company with the
SEC or required to be distributed or otherwise disseminated to the
Company’s stockholders in connection with the transactions
contemplated by this Agreement (the “ Company Disclosure
Documents ”), including the Schedule 14D-9, the
proxy or information statement of the Company (the “
Company Proxy Statement ”), if any, to be filed with
the SEC in connection with the Merger, and any amendments or
supplements thereto, when filed, distributed or disseminated, as
applicable, will comply as to form in all material respects with
the applicable requirements of the 1934 Act.
23
(b) (i) The Company Proxy Statement,
as supplemented or amended, if applicable, at the time such Company
Proxy Statement or any amendment or supplement thereto is first
mailed to stockholders of the Company and at the time such
stockholders vote on approval of the Merger and at the Effective
Time, and (ii) Company Disclosure Document (other than the
Company Proxy Statement), at the time of the filing of such Company
Disclosure Document or any supplement or amendment thereto and at
the time of any distribution or dissemination thereof, will not
contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were
made, not misleading. The representations and warranties contained
in this Section 5.09(b) will not apply to statements or
omissions included in the Company Disclosure Documents based upon
information furnished to the Company in writing by Parent or Merger
Subsidiary specifically for use therein.
(c) The information with respect to
the Company or any of its Subsidiaries that the Company furnishes
to Parent or Merger Subsidiary in writing specifically for use in
the Schedule TO and the Offer Documents, at the time of the filing
of the Schedule TO, at the time of any distribution or
dissemination of the Offer Documents and at the time of the
consummation of the Offer, will not contain any untrue statement of
a material fact or omit to state any material fact necessary in
order to make the statements made therein, in the light of the
circumstances under which they were made, not
misleading.
Section 5.10
. Absence of Certain Changes
. (a) Since the Company Balance Sheet Date, the business of
the Company and its Subsidiaries has been conducted in the ordinary
course consistent with past practices in all material respects and
there has not been any event, occurrence, development or state of
circumstances or facts that has had or would reasonably be expected
to have, individually or in the aggregate, a Company Material
Adverse Effect.
(b) Since the Company Balance Sheet
Date through the date hereof, (i) there has not been any
action taken by the Company or any of its Subsidiaries that, if
such action had been taken during the period from the date of this
Agreement through the Effective Time without Parent’s
consent, would constitute a breach of Section 7.01(b), (g),
(h), (i), (m)(ii) or (n) and (ii) none of the Company or
any of its Subsidiaries have settled any matter referenced in
clauses (A), (B) or (C) of
Section 7.01(m).
Section 5.11
. No Undisclosed Material
Liabilities . There are no material liabilities or obligations
of the Company or any of its Subsidiaries of any kind whatsoever,
whether accrued, contingent, absolute, determined, determinable or
otherwise, that would be required by GAAP to be reflected on a
consolidated balance sheet of the Company and its Subsidiaries (or
in the notes thereto) other
24
than (a) liabilities or obligations
disclosed in or reflected or reserved against in the
Company’s consolidated balance sheet or in the notes thereto
included in the Company’s most recent 10-Q filed prior to the
date of this Agreement and (b) liabilities or obligations
incurred in the ordinary course of business consistent with past
practices since the date of the Company’s consolidated
balance sheet included in the Company’s most recent 10-Q
filed prior to the date of this Agreement.
Section 5.12
. Compliance with Laws and Court
Orders . The Company and each of its Subsidiaries is and has
been in compliance with, and to the knowledge of the Company is not
under investigation with respect to and has not been threatened to
be charged with or given notice of any violation of, any Applicable
Law, except for failures to comply or violations that would not
reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect.
Section 5.13
. Litigation . There is no
material action, suit, arbitration, investigation or proceeding (or
any reasonable basis therefor) pending against, or, to the
knowledge of the Company, threatened against or affecting, the
Company or any of its Subsidiaries or any of their respective
properties, or, to the actual knowledge of the Company, threatened
against or affecting, any current or former officer, director or
employee of the Company or any of its Subsidiaries or any Person
for whom the Company or any of its Subsidiaries may be liable,
before (or, in the case of threatened actions, suits,
investigations or proceedings, that would be before) or by any
Governmental Authority (including any of the Food and Drug
Administration, Department of Health and Human Services, the Drug
Enforcement Administration, state Medicaid agencies, state pharmacy
boards and other federal or state Governmental Authorities with
jurisdiction over the dispensing or distribution of pharmaceutical
products or over the provision of health care items or services) or
arbitrator.
Section 5.14
. Regulatory Compliance
.
(a) The Permits of the Company and
each of its Subsidiaries are valid and in full force and effect,
and no violation or default exists under any such Permit, except
where the failure to hold any such Permit, the invalidity of such
Permit or the existence of any such violation or default would not
reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect. Assuming all Healthcare Regulatory
Approvals are obtained, the Merger, in and of itself, would not
cause the revocation or cancellation of any Permit except where the
revocation or cancellation of such Permit would not reasonably be
expected to have, individually or in the aggregate, a Company
Material Adverse Effect.
(b) Neither the Company nor any of
its Subsidiaries has received written notice from any Governmental
Authority that (i) alleges any material noncompliance (or that
the Company or any of its Subsidiaries is under
25
investigation or the subject of an inquiry by
any such